Skip to main content

Table 5 Predictors for treatment failure.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

Treatment group

Risk variables

Unadjusted OR (95% CI)

p-value

Adjusted OR (95% CI)*

p-value

SP (n = 50)

Parasite density

3.74 (1.12–12.54)

0.03

3.16 (0.73–13.71)

0.13

 

CIRN

4.67 (1.25–17.44)

0.02

7.21 (1.42–36.73)

0.02

 

GLURP-R0

0.09 (0.02–0.41)

0.002

0.08 (0.14–0.47)

0.005

AQ (n = 50)

Parasite density

0.82 (0.27–2.46)

0.72

0.77 (0.13–4.42)

0.76

 

CVIET

3.55 (0.85–14.91)

0.08

2.56 (0.46–14.27)

0.28

 

GLURP-R0

0.10 (0.02–0.43)

0.002

0.07 (0.01–0.48)

0.003

SP+AQ (n = 100)

Parasite density

1.61 (0.74–3.47)

0.23

1.13 (0.43–2.99)

0.80

 

CIRN/CVIET

3.76 (1.49–9.47)

0.005

3.44 (1.12–10.54)

0.03

 

GLURP-R0

0.13 (0.06–0.33)

< 0.001

0.11 (0.04–0.31)

< 0.001

  1. Multivariate regression models predicting failure of antimalarial treatment. SP: sulphadoxine-pyrimethamine, AQ: amodiaquine.OR: Odds Ratio, CI: 95% Confidence interval. CIRN: Presence of the triple dhfr CIRN haplotype. CVIET: Presence of the crt CVIET haplotype. CIRN/CVIET: Presence of parasites with CIRN in patients treated with SP and presence of parasites with CVIET in patients treated with AQ. GLURP-R0: Presence of IgG antibodies to GLURP-R0. SP+AQ: Total patients in the two treatment groups. *Adjusted for age, parasite density, presence of mutant haplotypes and GLURP-R0 antibodies. No interaction between presence of mutant haplotypes and GLURP-R0 IgG antibodies was detected.